BioSpace News Archive

Ensysce Biosciences, Inc. has appointed David J. Kovacs to the new position of VP Public Policy and David Tanzer to the new position of VP Strategic Development, both effective July 22, 2021.

Intec Pharma Ltd., announced that its wholly-owned subsidiary, Intec Parent, Inc., entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement.

Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights.

Twist Bioscience Corporation today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal pipeline of antibody candidates.

Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business Update to the market.

WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility in Leverkusen, Germany.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.

Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close.

PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.

7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced the appointment of Michael S. Perry, DVM, Ph.D., as its first Chairman of the Board of Managers.